Phase I/II Study of Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients With Follicular Lymphoma

Trial Profile

Phase I/II Study of Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients With Follicular Lymphoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Epratuzumab Y-90 (Primary) ; Veltuzumab (Primary)
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Apr 2017 Status changed from active, no longer recruiting to discontinued due to slow patient accrual.
    • 07 Feb 2017 Planned End Date changed from 1 Jun 2013 to 31 Dec 2017.
    • 07 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top